Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modulators of the G protein-coupled formyl peptide receptor-like 2 and their therapeutic use against cell death-related disorders

A technology for coupling receptors and regulators, applied in the field of human G protein-coupled receptors and its regulators for the treatment of cell death-related diseases, can solve the problem of under-discovery

Inactive Publication Date: 2009-07-15
ARENA PHARMA
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Humanin immunoreactivity has been detected in the brain of an Alzheimer's patient, but rarely in normal human brains [Tajima et al., Neurosci Lett (2002) 324: 227-31]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulators of the G protein-coupled formyl peptide receptor-like 2 and their therapeutic use against cell death-related disorders
  • Modulators of the G protein-coupled formyl peptide receptor-like 2 and their therapeutic use against cell death-related disorders
  • Modulators of the G protein-coupled formyl peptide receptor-like 2 and their therapeutic use against cell death-related disorders

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[1335] for radioactive levels 125 The synthetic method that I is incorporated in the target molecule comprises:

[1336] A. Sandmeyer and its analogues - This procedure converts an aryl or heteroaryl amine to a diazonium salt, such as tetrafluoroborate, and subsequently uses Na 125 I convert it to 125 I labeled compound. Zhu, D.-G. and co-workers report their representative procedure in J. Org. Chem. 2002, 67: 943-948.

[1337] B. Ortho-iodination of phenols ( 125 I) - This procedure allows incorporation of the ortho position of the phenol 125 I, as reported by Collier, T.L. and colleagues in J. Labeled Compd Radiopharm. 1999, 42, S264-S266.

[1338] C. Aryl and heteroaryl bromides with 125 I Exchange - This method is usually a two-step process. The first step is to use (for example) Pd to catalyze the reaction [i.e. Pd(Ph 3 P) 4 ] or via aryl or heteroaryl lithium, in a trialkyltin halide or hexaalkylditin [eg (CH 3 ) 3 SnSn(CH 3 ) 3 ] to convert aryl or heteroar...

example

[1343] The following examples are presented to illustrate the invention, not to limit it. While specific nucleic acid and amino acid sequences are disclosed herein, we believe that minor modifications of those sequences are within the ability of those skilled in the art to obtain results that are identical or substantially similar to those reported hereinafter. The mutagenesis method disclosed herein does not rely on this method, but is based on the algorithm and the positional distance apart from the conserved proline residues located in the TM6 domain of the human GPCR. Once this method is solid, it is believed within the ability of those skilled in the art to make minor modifications to achieve substantially the same results as those disclosed herein (ie, constitutive activation). We consider such modification methods to be within the scope of the present disclosure.

[1344] The following examples are offered for purposes of illustration and not in a limiting manner. Tho...

example 1

[1347] Full-length cloning of human GPCRs

[1348] a. Endogenous human FPRL2 (SEQ ID NO: 1 and SEQ ID NO: 2)

[1349] The polynucleotide sequence encoding full-length FPRL2 (Gene Sequence Database Accession No. L14061) was cloned as described herein. SEQ ID NO: 1 is the human FPRL2 polynucleotide coding sequence. SEQ ID NO: 2 is the encoded FPRL2 polypeptide. We believe that those skilled in the art have the ability to make minor modifications to the experimental protocols presented herein to similarly clone endogenous human FPRL1 (Gene Sequence Database Accession No. AF054013) polynucleotide and endogenous human FPR (gene Sequence Database Accession No. M60627) polynucleotide.

[1350] PCR was performed using genomic DNA as template and rTth polymerase (PerMn Elmer) with buffer system provided by the manufacturer, 0.25 mM of each primer and 0.2 mM of each 4 nucleotides. Cycling conditions were 30 cycles of 94°C for 1 minute, 64°C for 1 minute and 72°C for 1 minute and 20 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is endogenously expressed by nerve cells or muscle cells. In certain embodiments, the GPCR is neuroprotective or myoprotective. In certain embodiments, the GPCR is a Humanin receptor. The invention also relates to methods of using said modulators of GPCRs. A preferred modulator is an agonist. The agonists of the present invention are generally used as therapeutic agents to prevent or treat neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, prions Associated diseases, stroke and motor neurone disease, especially peripheral neuropathy, cerebral amyloid beta-protein angiopathy and ischemic heart disease, including myocardial infarction and congestive heart failure.

Description

[0001] This application claims priority to the following provisional applications filed with the United States Patent and Trademark Office by U.S. Express Mail on the indicated dates: U.S. Provisional Application Nos. 60 / 455316 filed March 17, 2003 and December 22, 2003 U.S. Provisional Application No. 60 / 532001 filed on . The disclosures of the above applications are incorporated herein by reference in their entirety. technical field [0002] The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is endogenously expressed by neuronal or muscle cells. In certain embodiments, the GPCR is neuroprotective or myoprotective. In certain embodiments, the GPCR is a humanin receptor. The invention also relates to methods of using said modulators of GPCRs. A preferred modulator is an agonist. The agonists of the present in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/74G01N33/566C07C233/58C07C235/40C07C237/24C07C311/16C07C323/62C07C317/44C07C237/42C07C237/48C07C255/57
Inventor 索尼娅·比列加斯格雷戈里·克尔纳戴维·阿纳特乔尔·加特林
Owner ARENA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com